Aladote® (calmangafodipir)
Prevention of Acute Liver Injury from Paracetamol/Acetaminophen Overdose
Phase IIb/III (Planned)Active (Study start postponed)
Key Facts
Indication
Prevention of Acute Liver Injury from Paracetamol/Acetaminophen Overdose
Phase
Phase IIb/III (Planned)
Status
Active (Study start postponed)
Company
About Egetis Therapeutics
Egetis Therapeutics is an integrated pharmaceutical company executing a de-risked, late-stage orphan drug strategy. Its core achievement is the EU marketing authorization and launch in Germany for Emcitate® (tiratricol), the first-ever treatment for the ultra-rare Allan-Herndon-Dudley Syndrome (MCT8 deficiency), with a US NDA under Priority Review. The company's strategy centers on advancing this asset through global approvals and commercialization while preparing its second program, Aladote®, for pivotal studies, aiming to build a sustainable portfolio of niche therapies.
View full company profile